<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480294</url>
  </required_header>
  <id_info>
    <org_study_id>HRS5091-101</org_study_id>
    <nct_id>NCT04480294</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Oral HRS5091 in Healthy Subjects and Chronic Hepatitis B Patients</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics of Oral HRS5091 in Healthy Subjects With Single or Multiple Dose and Chronic Hepatitis B Patients With Multiple Dose, and Food Effects of HRS5091 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety,&#xD;
      tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS5091. The study&#xD;
      will be conducted in three parts sequentially:&#xD;
&#xD;
      Part 1a will consist of 58 healthy subjects, 5 groups. The purpose of this part is to explore&#xD;
      the safety, tolerability and pharmacokinetics of single doses of HRS5091 tablet in healthy&#xD;
      subjects.&#xD;
&#xD;
      Part 1b will consist of 18 healthy subjects and it is one of groups in Part 1a.The purpose of&#xD;
      this part is to explore food effect of HRS5091 in healthy subjects.&#xD;
&#xD;
      Part 1c will consist of 10 healthy subjects, 1 groups. The purpose of this part is to explore&#xD;
      the safety, tolerability and pharmacokinetics of multiple doses of HRS5091 tablet in healthy&#xD;
      subjects.&#xD;
&#xD;
      Part 2 will consist of 30 CHB patients.The purpose of this part is to explore the safety,&#xD;
      tolerability and pharmacokinetics, pharmacodynamics of multiple doses of HRS5091 tablet in&#xD;
      naïve and treatment-discontinued chronic hepatitis B (CHB) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">November 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of treatment-related</measure>
    <time_frame>29 DAYS for Group 1.2.4.5; 58 DAYS for Group 3; 42 DAYS for Group 6；56 DAYS for Group 7-9；</time_frame>
    <description>adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration time curve [AUC]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration [Tmax]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance [CL/F]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-time [t1/2]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution [Vz/F(Vd)]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean retention time [MRT]</measure>
    <time_frame>0-672 hours after each dose for Group 1-9</time_frame>
    <description>Pharmacokinetic parameters of HRS5091, main metabolite and identified major metabolites in plasma</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Part 1a Treatment group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 1; Drug2: Placebo Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1a Treatment group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 2; Drug2: Placebo Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1a Treatment group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1a Treatment group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1a Treatment group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b Treatment group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects Food effect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c Treatment group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Treatment group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 3; Drug2: Placebo CHB subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Treatment group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 4; Drug2: Placebo CHB subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Treatment group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug1: HRS5091, dose 5; Drug2: Placebo CHB subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS5091</intervention_name>
    <description>Single dose in group 1-5&#xD;
Multiple doses in group 6-9</description>
    <arm_group_label>Part 1a Treatment group 1</arm_group_label>
    <arm_group_label>Part 1a Treatment group 2</arm_group_label>
    <arm_group_label>Part 1a Treatment group 3</arm_group_label>
    <arm_group_label>Part 1a Treatment group 4</arm_group_label>
    <arm_group_label>Part 1a Treatment group 5</arm_group_label>
    <arm_group_label>Part 1b Treatment group 3</arm_group_label>
    <arm_group_label>Part 1c Treatment group 6</arm_group_label>
    <arm_group_label>Part 2 Treatment group 7</arm_group_label>
    <arm_group_label>Part 2 Treatment group 8</arm_group_label>
    <arm_group_label>Part 2 Treatment group 9</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
               1. Signed informed consent.&#xD;
&#xD;
               2. Aged 18~55.&#xD;
&#xD;
               3. Body weight ≥ 50 kg for male; ≥ 45 kg for female, body mass index (BMI) between&#xD;
                  18 to 28 kg/m².&#xD;
&#xD;
               4. Vital signs, physical examination, laboratory results are within normal range or&#xD;
                  considered not clinically significant.&#xD;
&#xD;
               5. Female subjects (including partner) of childbearing potential must be using a&#xD;
                  medically acceptable form of birth control.&#xD;
&#xD;
          -  CHB subjects&#xD;
&#xD;
               1. Signed informed consent.&#xD;
&#xD;
               2. Aged 18~65.&#xD;
&#xD;
               3. CHB subjects should meet one of the following two criteria:&#xD;
&#xD;
                    -  IgM(immunoglobulin M) HBcAb negative and HBsAg positive.&#xD;
&#xD;
                    -  Two recorded HBsAg positive, and the time interval between the two tests was&#xD;
                       at least 6 months, one of which was the result of this screening&#xD;
&#xD;
               4. CHB subjects should also meet the following criteria:&#xD;
&#xD;
                    -  No treatment with nucleosides analogues or discontinued treatment with&#xD;
                       nucleosides analogues least 6 months at screening&#xD;
&#xD;
                    -  Have not received interferon therapy or discontinued treatment with&#xD;
                       interferon analogues least 3 months at screening&#xD;
&#xD;
                    -  HBeAg positive，HBV(hepatitis B virus) DNA≥ 20000 IU/mL; HBeAg negative, HBV&#xD;
                       DNA≥ 2000 IU/mL&#xD;
&#xD;
                    -  ALT(Alanine aminotransferase)&gt; 1 ULN(upper limit of normal) by two&#xD;
                       measurements within 6 months before enrollment.The interval between two&#xD;
                       measurements shall exceed 14 days;&#xD;
&#xD;
               5. Female subjects (including partner) of childbearing potential must be using a&#xD;
                  medically acceptable form of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
               1. Currently suffering from cardiovascular, liver, kidney, digestive, nervous,&#xD;
                  blood, thyroid or mental diseases.&#xD;
&#xD;
               2. Have a digestive system disease or a medical history of severe digestive system&#xD;
                  disease at present or in the past month.&#xD;
&#xD;
               3. Have severe infection, severe trauma or major surgical operations within 3&#xD;
                  months. Plan to receive surgery during the trial and within two weeks after the&#xD;
                  end of the trial.&#xD;
&#xD;
               4. 12-ECG test have clinical significant abnormality or the QT interval (QTc) &gt; 470&#xD;
                  ms(male)/QTc)&gt; 480 ms(male) or&lt;300ms(female).&#xD;
&#xD;
               5. Have a medical history of immune-mediated diseases.&#xD;
&#xD;
               6. Screening for infectious diseases is positive,Including HBsAg, Anti-HCV(hepatitis&#xD;
                  C virus), TPPA(Treponema pallidum particle agglutination assay),&#xD;
                  Anti-HIV.Treponema pallidum antibody screen positive, at the investigator's&#xD;
                  discretion in conjunction with RPR(rapid plasma reagin assay) results.&#xD;
&#xD;
               7. Suspected allergy to any ingredient in the study drug.&#xD;
&#xD;
               8. Have any drug that inhibits or induces liver metabolism within 1 month.&#xD;
&#xD;
               9. Take any prescription drugs, over-the-counter drugs and Chinese herbal medicines&#xD;
                  within 14 days before taking the study drug, or plan to take other drugs during&#xD;
                  the test period.&#xD;
&#xD;
              10. Participated in clinical trials of any drug or medical device within 3 months&#xD;
                  before screening.&#xD;
&#xD;
              11. Had donated blood/blood transfusion≥ 200 mL within 1 months prior to screening or&#xD;
                  donated blood or blood transfusion≥ 450 mL within 3 months prior to screening.&#xD;
&#xD;
              12. The average daily smoking ≥ 5 cigarettes within three months; the average daily&#xD;
                  alcohol intake in a month exceeds 15 g (15 g alcohol is equivalent to 450 mL beer&#xD;
                  or 150 mL wine or 50 mL low-alcohol);&#xD;
&#xD;
              13. Keep smoking, drinking alcohol or consuming caffeinated foods or beverages (more&#xD;
                  than 8 cups, 1 cup = 250 mL) 2 days before taking the study drug and during the&#xD;
                  study; and those who have special dietary requirements and cannot follow the&#xD;
                  unified diet;&#xD;
&#xD;
              14. Pregnant or lactating women;&#xD;
&#xD;
              15. Drug screening or alcohol breath test is positive.&#xD;
&#xD;
              16. Other conditions that the investigator believes the subject is not suitable.&#xD;
&#xD;
          -  CHB subjects&#xD;
&#xD;
               1. Currently suffering from serious cardiovascular, liver, kidney, digestive,&#xD;
                  nervous, blood, thyroid or mental diseases other than hepatitis B.&#xD;
&#xD;
               2. People have acute or chronic liver disease by non-HBV infection (Whether fatty&#xD;
                  liver is excluded or not is determined by the investigator).&#xD;
&#xD;
               3. Liver stiffness (LSM)&gt; 12.4 kPa(kilopascal) by noninvasive transient liver&#xD;
                  elastography (eg Fibroscan®) or recorded liver biopsy suggesting cirrhosis or&#xD;
                  extensive fibrosis within 6 months before randomization.&#xD;
&#xD;
               4. Primary liver cancer, high-risk groups of primary liver cancer or AFP(alpha&#xD;
                  fetoprotein)&gt; 50g/L;&#xD;
&#xD;
               5. Have clinically demonstrated or history of liver function decompensation,&#xD;
                  including but not limited to: hepatic encephalopathy, hepatorenal syndrome,&#xD;
                  splenomegaly, ascites, etc.;&#xD;
&#xD;
               6. Laboratory inspection:&#xD;
&#xD;
                    1. Platelet count &lt;90×10⁹/L;&#xD;
&#xD;
                    2. White blood cell count &lt;3.0×10⁹/L;&#xD;
&#xD;
                    3. Absolute value of neutrophils &lt;1.5×10⁹/L;&#xD;
&#xD;
                    4. Serum total bilirubin&gt;2×ULN;&#xD;
&#xD;
                    5. Albumin &lt;30 g/L;&#xD;
&#xD;
                    6. Creatinine clearance rate ≤60ml/min;&#xD;
&#xD;
                    7. INR(international normalized ratio)&gt;1.5;&#xD;
&#xD;
                    8. ALT&gt; 5 ULN on screening/baseline visit&#xD;
&#xD;
               7. HIV and/or syphilis antibody positive (Treponema pallidum antibody screen&#xD;
                  positive, at the investigator's discretion in conjunction with RPR results).&#xD;
&#xD;
               8. Subjects who have previously received organ/bone marrow transplantation;&#xD;
&#xD;
               9. Have used immunosuppressants, immunomodulators or cytotoxic drugs within 6 months&#xD;
                  before the study medication;&#xD;
&#xD;
              10. Suspected allergy to any ingredient in the study drug.&#xD;
&#xD;
              11. 12-ECG test have clinical significant abnormality or the QT interval (QTc) &gt; 470&#xD;
                  ms(male)/QTc)&gt; 480 ms(male) or&lt;300ms(female).&#xD;
&#xD;
              12. The average daily smoking ≥ 5 cigarettes within three months; the average daily&#xD;
                  alcohol intake in a month exceeds 15 g (15 g alcohol is equivalent to 450 mL beer&#xD;
                  or 150 mL wine or 50 mL low-alcohol);&#xD;
&#xD;
              13. Keep smoking, drinking alcohol or consuming caffeinated foods or beverages (more&#xD;
                  than 8 cups, 1 cup = 250 mL) 2 days before taking the study drug and during the&#xD;
                  study; and those who have special dietary requirements and cannot follow the&#xD;
                  unified diet;&#xD;
&#xD;
              14. Pregnant or lactating women;&#xD;
&#xD;
              15. Drug screening or alcohol breath test is positive.&#xD;
&#xD;
              16. Other conditions that the investigator believes the subject is not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

